Shots:

• The 1^st patient has been dosed in the P-I trial to evaluate the safety- tolerability & PK of GFB-024 vs. PBO in patients with severe insulin-resistant DN and inhibit CB1 pathway. The company expects to report initial data in 2022
• The trial will also assess repeat dosing of GFB-024 in patients with type 2 diabetes mellitus to evaluate immunogenicity- PK- and safety while GFB-887 is currently in P-II TRACTION-2 trial for FSGS and DN
• The preclinical studies showed that GFB-024 inhibits CB1 receptor signalling and protects against podocyte and tubular cell injury- no physiological effect in CNS. Additionally- the trial will explore the biomarkers to confirm peripheral CB1 target

  Ref: BUSINESS WIRE | Image: Goldfinch Bio